Antinociceptive effect of intracerebroventricular administration of cholecystokinin receptor agonist and antagonist in Nerve-Ligated mice

Pharmacology and Toxicology

Volumn 87, Issue 4, 2000, Pages 169-173

  Zarrindast, Mohammad Reza ^a   Samiee, Farzaneh ^a   Rezayat, Mehdi ^a  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

[No Author keywords available]

Indexed keywords

CERULETIDE; CHOLECYSTOKININ; CHOLECYSTOKININ RECEPTOR; MORPHINE; PROGLUMIDE;

ANIMAL EXPERIMENT; ANTINOCICEPTION; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG ANTAGONISM; DRUG MECHANISM; DRUG POTENTIATION; MALE; MOUSE; NERVE LIGATION; NONHUMAN; PRIORITY JOURNAL; SCIATIC NERVE;

ANIMALIA;

EID: 0033791285     PISSN: 09019928     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1600-0773.2000.pto870404.x     Document Type: Article

References (40)

1. Attal, N., F. Gauziest, V. Kayser & G. Guilbaund: Further evidence for 'pain-related' behaviors in a model of unilateral peripheral mononeuropathy. Pain 1990; 41, 235-251.
2. Baber, N. S., C. T. Dourish & D. R. Hill: The role of CCK, caerulein and CCK antagonist in nociception. Pain 1989, 39, 307-328.
3. Barbaz, B. S., W. L. Autry, F. G. Ambrose, N. R. Hall & J. M. Liebman: Antinociceptive profile of sulphated CCK-8. Neuropharmacology 1986, 25, 823-829.
4. Benedetti, E: Cholecystokinin type A and type B receptors and their modulation of opioid analgesia. News Physiol. Sci. 1997, 12, 263-268.
5. Bennett, G. J. & Y. K. Xie: A peripheral mononeuropathy in rat that produces disorders of pain sensation like those seen in man. Pain 1988, 33, 87-107.
6. Bock, M. G.: Development of non-opioid cholecystokinin type B receptor antagonists. Drug Future 1991, 16, 631-640.
7. Chiodo, L. A. & B. S. Nenney: Proglumide, selective antagonism of excitatory effect of cholecystokinin in central system. Science 1983, 19, 1449-1450.
8. Chiodo, L. A. & B. S. Nenney: Proglumide, selective antagonism of cholecystokinin in central system. Science 1985, 230, 177-179.
9. Coutinho, S. V, M. O. Urban & G. F. Gebhart: Role of glutamate receptors and nitric oxide in the rostal ventromedial medulla in visceral hyperalgesia. Pain 1998, 78, 59-69.
10. B, agonists suppress the hyperlocomotion induced by endogenous enkephalins, protected from enzymatic depradation by systemic RB 101. Pharmacol. Biochem. Behav. 1995, 50, 133-139.
11. Derrien, M., F. Noble, R. Maldonado & B. P. Roques: Cholecystokinin-A but not cholecystokinin-B receptor stimulation induces endogenous opioid-dependent antinociceptive effects in the hot-plate test in mice. Neurosci. Lett. 1993, 160, 193-196.
12. Dourish, C. T. & R. G. Hill: Classification and function of CCK receptors. Trends Pharmacol. Sci. 1987, 8, 207-208.
13. Eddy, N. B. & D. Leimbach: Synthetic analgesics. II. Dithienylbutyl and dithienylbutylamines. J. Pharmacol. Exp. Therap. 1953, 107, 385-393.
14. Faris, P. L., B. R. Komisaruk, L. R. Watkins & D. A. Mayer: Evidence for the neuropeptide cholecystokinin as an antagonist of opiate analgesia. Science 1983, 219, 310-312.
15. Filliatreau, G., N. Attal, R. Hassig, G. Guilbaud, J. Desmeubles & L. DiGiamberardino: Time-course of nociceptive disorders induced by chronic loose ligatures of the rat sciatic nerve and changes of the acetylcholinesterase transport along the ligated nerve. Pain 1994, 59, 405-413.
16. Foley, K. M.: Clinical tolerance to opioids. In: Towards a new pharmacology of pain. Eds.: A. I. Bashaum and J. M. Besson. John Wiley, Chicester, 1991, pp. 181-204.
17. Hill, R. G., J. Hughes & K. M. Pittaway: Antinociceptive action of cholecystokinin octapeptide (CCK-8) and related peptides in rats and mice: Effects of naloxone and peptidase inhibitors. Neuropharmacology 1987, 26, 289-300.
18. Hill, D. R. & G. N. Woodruff: Differentiation of central cholecystokinin receptor binding sites using the non-peptide antagonists MK-329 and L-365, 260. Brain Res. 1990, 526, 276-283.
19. Holladay, M. K. & C. W. Lin: CCK agonist: a summery of structure-activity relationships with a focus on A-71378, a potent selective CCK-A agonist. Drugs Future 1992, 17, 197-206.
20. Inturrisi, C. E.: Opioid analgesic therapy in cancer pain. In: Advances in pain research and therapy. Eds.: K. M. Foley, J. J. Bonica and V. Ventafridds. Raven Press, New York, pp. 1990, 133-154.
21. Itoh, S., G. Katsuura & Y. Maeda: Caerulein and cholecystokinin suppress β-endorphin-induced analgesia in the rat. Eur. J. Pharmacol. 1982, 80, 421-425.
22. Jacobs, J. M.: The role of the saphenous nerve in experimental sciatic nerve mononeurophathy produced by loose ligatures: a behavioural study. Pain 1993, 52, 359-369.
23. Jiang, G., H. I. Mosberg & F. Porreca: Selective modulation of morphine antinociception, by δ receptor. Eur. J. Pharmacol. 1990, 186,137-141.
24. Katsuura, G. & S. Itoh: Potentiation of endorphine effects by proglumide in rats. Eur. J. Pharmacol. 1985, 107, 363-366.
25. Kellstain, D. E. & D. J. Mayer: Spinal co-administration of cholecystokinin antagonists with morphine prevents the development of opioid tolerance. Pain 1991, 47, 221-229.
26. Magnuson, D. S. K., A. F. Sullivan, G. Simonnet, B. P. Request & A. H. Dickenson: Differential interactions of cholecystokinin and FLFQPARE-NH2 with μ and δ opioid analgesia in the rat spinal cord. Neuropharmacology 1990, 16, 213-218.
27. Mao, J. D. D. Price & D. J. Mayer: Experimental mononeuropathy reduces the antinociceptive effects of morphine: implications for common intracellular mechanisms involved in morphine tolerance and neuropathic pain. Pain 1995, 61, 353-364.
28. Moran, T. H., P. H. Robinson, M. S. Goldrich & P.R. McHugh: Two brain cholecystokinin receptors: Implications for behavioral actions. Brain Res. 1986, 362, 175-179.
29. Nichols, M. L., Y. Lopez, M. H. Ossipov, D. Bian & F. Porreca: Enhancement of the antiallodynic and antinociceptive efficacy of spinal morphine by antisera to dynorphin A (1-13) or MK-801 in a nerve-ligation model of peripheral neuropathy. Pain 1997, 69, 317-322.
30. Ossipov, M. H., M. L. Nichols, D. Bian & F. Porreca: Inhibition by spinal morphine of the tail-flick response is attenuated in rats with nerve ligation injury. Neurosci. Lett. 1995, 199, 1-4.
31. Slaninova, J., R. J. Knapp, J. Wu, S. N. Fang, T. Kranier, T. F. Burks, V. J. Hruby & H. I. Yamamura: Opioid receptor binding properties of analgesic analogues of cholecystokinin octapeptide. Eur. J. Pharmacol 1991, 200, 195-198.
32. Suh, H. H., K. A. Collins & F. Tseng: Intrathecal cholecystokinin octapeptide attenuates the analgesia and release of immunoreactive Met-enkephalin induced by intraventricular-endorphin in the rat. Neuropeptides 1992, 21, 131-136.
33. Tiseo, P. J., J. Cheng, G. W. Pasternak & C. E. Inturrisi: Modulation of morphine tolerance by the competitive N-methyl-D-aspartate receptor antagonist LY274614: assessment of opioid receptor changes. J. Pharmacol. Exp. Therap. 1994, 268, 195-201.
34. Wiesenfeld-Hallin, Z., H. Aldskogius, G. Grant, J. X. Hao, T. Hökfelt & J. Xu: Central inhibitory disfunction: mechanism and clinical implication. Behav. Brain. Sci. 1997, 20, 420-425.
35. Woodruff, G. N. & J. Hughes: Cholecystokinin antagonists. Ann. Rev. Pharmacol. Toxicol 1991, 31, 469-501.
36. Xu, X. J., M. J. C. Puke, V. M. K. Verge, Z. Wiesenfeld-Hallin, J. Hughes & T. Hökfelt: Upregulation of cholecystokinin in primary sensory neurons is associated with morphine insensivity in experimental neuropathic pain in the rat. Neurosci. Lett. 1993, 152, 129-132.
37. Xu, X. J., T. Hökfelt, J. Hughes & Z. Wiesenfeld-Hallin: The CCK-B antagonist C1988 enhances the reflex-depressive effect of morphine in axotomized rats. Neuro Report 1994, 5, 718-720.
38. Zarrindast, M. R. & M. Rezayat: Caerulein changes morphine-induced analgesia depending on pretreatment times. Gen. Pharmacol. 1994, 25, 311-316.
39. Zarrindast, M. R., A. Zabihi, M. Rezayat, H. Rakhshandeh, M. Ghazi-Khansari & R. Hosseini: Effects of caerulein and CCK antagonists on tolerance induced to morphine antinociception in mice. Pharmacol. Biochem. Behav. 1997, 58, 173-178.
40. Zetler, G.: Cholecystokinin octapeptide, caerulein and caerulein analogues: effect on thermoregulation in the mouse. Neuropharmacology 1982, 21, 795-801.